Zemaira is an alpha1 -proteinase inhibitor (A1 -PI) indicated for chronic augmentation and maintenance therapy in adults with A1 -PI deficiency and clinical evidence of emphysema.
Alpha1 antitrypsin (A1AT) deficiency, or Alpha-1 for short, is a hereditary and progressive condition that affects your lungs. It’s passed down from parent to child through their genes.
Zemaira was proven in clinical trials to raise and maintain levels of the Alpha-1 protein.
Zemaira is an intravenous infusion that generally takes about 15 to 30 minutes. Glassia is administered weekly, and dosing is weight based.
Potential Side Effects
In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.
For a full list of potential side effects, please see the Important Safety Information and Medication Guide on the Zemaira website.
Before you attend your first appointment at Sage Infusion, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!
Find a Sage Infusion Location Near You
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
SEARCH BY ZIP